{"transactions":[{"id":4640757,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22786,"kind":"person","name":"Ray Sumita","position":1,"cik":"0001579629","reported_name":"Ray Sumita","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Legal Compliance Officer","other_text":"Corporate Secretary"}}],"security":"Common Stock","published_at":"2026-10-15T01:39:34.000Z","date":"2026-10-12","kind":"sale","planned":false,"acquired":false,"shares":1844,"price":28.05,"value":51724.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a \"sell-to-cover\" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold."}],"balance_after":116701,"source":{"system":"sec-edgar","filing":"0001579629-26-000012","document":"form4-10152026_011030.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000157962926000012/form4-10152026_011030.xml","form_type":"4"}},{"id":4640756,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22764,"kind":"person","name":"Meluzio Michael Vincent","position":1,"cik":"0002138368","reported_name":"Meluzio Michael Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Prin. Accounting Officer"}}],"security":"Common Stock","published_at":"2026-10-15T01:38:15.000Z","date":"2026-10-12","kind":"sale","planned":false,"acquired":false,"shares":1144,"price":28.05,"value":32089.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a \"sell-to-cover\" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold."}],"balance_after":47817,"source":{"system":"sec-edgar","filing":"0002138368-26-000009","document":"form4-10152026_011010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2138368/000213836826000009/form4-10152026_011010.xml","form_type":"4"}},{"id":4640755,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-15T01:37:35.000Z","date":"2026-10-12","kind":"sale","planned":false,"acquired":false,"shares":1087,"price":28.05,"value":30490.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a \"sell-to-cover\" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold."}],"balance_after":694908,"source":{"system":"sec-edgar","filing":"0001725092-26-000019","document":"form4-10152026_011031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000172509226000019/form4-10152026_011031.xml","form_type":"4"}},{"id":4640754,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-15T01:37:35.000Z","date":"2026-10-12","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":27.5,"value":275000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a \"sell-to-cover\" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold."}],"balance_after":695995,"source":{"system":"sec-edgar","filing":"0001725092-26-000019","document":"form4-10152026_011031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000172509226000019/form4-10152026_011031.xml","form_type":"4"}},{"id":673161,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":18808,"kind":"person","name":"Sarraf Pasha","position":1,"cik":"0002059447","reported_name":"Sarraf Pasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T17:05:23.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":18400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment is being filed solely to correct an administrative calculation error in Column 4 of Table I of the original filing relating to a grant of restricted stock units (\"RSUs\") to the Reporting Person, which resulted in the number of securities acquired by the Reporting Person being overstated. The original filing incorrectly reported 21,800 shares; the correct amount of shares acquired is 18,400. As a result of this correction, the total amount of securities beneficially owned following the reported transaction in Column 5 has been updated to 29,195. One-third of the shares subject to the RSU vest on each of July 9, 2027, July 9, 2028 and July 9, 2029, subject to the Reporting Person's continued service with the Issuer through each such vest date."}],"balance_after":29195,"source":{"system":"sec-edgar","filing":"0002059447-26-000006","document":"form4a-08282026_090818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2059447/000205944726000006/form4a-08282026_090818.xml","form_type":"4/A","original_submission_date":"2026-07-10"}},{"id":672735,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":18637,"kind":"person","name":"Garzone Pamela","position":1,"cik":"0001974756","reported_name":"Garzone Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-28T17:04:26.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":18900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment is being filed solely to correct an administrative calculation error in Column 4 of Table I of the original filing relating to a grant of restricted stock units (\"RSUs\") to the Reporting Person, which resulted in the number of securities acquired by the Reporting Person being overstated. The original filing incorrectly reported 21,800 shares; the correct amount of shares acquired is 18,900. As a result of this correction, the total amount of securities beneficially owned following the reported transaction in Column 5 has been updated to 18,900. One-third of the shares subject to the RSU vest on each of July 9, 2027, July 9, 2028 and July 9, 2029, subject to the Reporting Person's continued service with the Issuer through each such vest date."}],"balance_after":18900,"source":{"system":"sec-edgar","filing":"0001974756-26-000006","document":"form4a-08282026_090821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000197475626000006/form4a-08282026_090821.xml","form_type":"4/A","original_submission_date":"2026-07-10"}},{"id":685165,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22786,"kind":"person","name":"Ray Sumita","position":1,"cik":"0001579629","reported_name":"Ray Sumita","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Legal Compliance Officer","other_text":"Corporate Secretary"}}],"security":"Common Stock","published_at":"2026-08-17T22:22:36.000Z","date":"2026-08-13","kind":"exercise","planned":false,"acquired":false,"shares":18196,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The performance stock units (\"PSU\") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 13, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The performance stock units (\"PSU\") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 13, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The performance stock units (\"PSU\") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 13, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days."}],"balance_after":36393,"derivative":{"underlying":"Common Stock","underlying_shares":18196},"source":{"system":"sec-edgar","filing":"0001579629-26-000008","document":"form4-08172026_100832.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1579629/000157962926000008/form4-08172026_100832.xml","form_type":"4"}},{"id":685164,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22786,"kind":"person","name":"Ray Sumita","position":1,"cik":"0001579629","reported_name":"Ray Sumita","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Legal Compliance Officer","other_text":"Corporate Secretary"}}],"security":"Common Stock","published_at":"2026-08-17T22:22:36.000Z","date":"2026-08-13","kind":"sale","planned":false,"acquired":false,"shares":4,"price":31.13,"value":124.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."}],"balance_after":118545,"source":{"system":"sec-edgar","filing":"0001579629-26-000008","document":"form4-08172026_100832.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1579629/000157962926000008/form4-08172026_100832.xml","form_type":"4"}},{"id":685163,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22786,"kind":"person","name":"Ray Sumita","position":1,"cik":"0001579629","reported_name":"Ray Sumita","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Legal Compliance Officer","other_text":"Corporate Secretary"}}],"security":"Common Stock","published_at":"2026-08-17T22:22:36.000Z","date":"2026-08-13","kind":"sale","planned":false,"acquired":false,"shares":6442,"price":30.35,"value":195514.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $29.99 to $30.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades."}],"balance_after":118549,"source":{"system":"sec-edgar","filing":"0001579629-26-000008","document":"form4-08172026_100832.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579629/000157962926000008/form4-08172026_100832.xml","form_type":"4"}},{"id":685162,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22786,"kind":"person","name":"Ray Sumita","position":1,"cik":"0001579629","reported_name":"Ray Sumita","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Legal Compliance Officer","other_text":"Corporate Secretary"}}],"security":"Common Stock","published_at":"2026-08-17T22:22:36.000Z","date":"2026-08-13","kind":"sale","planned":false,"acquired":false,"shares":2383,"price":29.37,"value":69988.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $28.97 to $29.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades."}],"balance_after":124991,"source":{"system":"sec-edgar","filing":"0001579629-26-000008","document":"form4-08172026_100832.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579629/000157962926000008/form4-08172026_100832.xml","form_type":"4"}},{"id":685161,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22786,"kind":"person","name":"Ray Sumita","position":1,"cik":"0001579629","reported_name":"Ray Sumita","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Legal Compliance Officer","other_text":"Corporate Secretary"}}],"security":"Common Stock","published_at":"2026-08-17T22:22:36.000Z","date":"2026-08-13","kind":"exercise","planned":false,"acquired":true,"shares":18196,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":127374,"source":{"system":"sec-edgar","filing":"0001579629-26-000008","document":"form4-08172026_100832.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579629/000157962926000008/form4-08172026_100832.xml","form_type":"4"}},{"id":685122,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22764,"kind":"person","name":"Meluzio Michael Vincent","position":1,"cik":"0002138368","reported_name":"Meluzio Michael Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Prin. Accounting Officer"}}],"security":"Common Stock","published_at":"2026-08-17T22:19:56.000Z","date":"2026-08-13","kind":"exercise","planned":false,"acquired":false,"shares":13647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The performance stock units (\"PSU\") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 13, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The performance stock units (\"PSU\") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 13, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The performance stock units (\"PSU\") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 13, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days."}],"balance_after":27295,"derivative":{"underlying":"Common Stock","underlying_shares":13647},"source":{"system":"sec-edgar","filing":"0002138368-26-000007","document":"form4-08172026_100852.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000213836826000007/form4-08172026_100852.xml","form_type":"4"}},{"id":685121,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22764,"kind":"person","name":"Meluzio Michael Vincent","position":1,"cik":"0002138368","reported_name":"Meluzio Michael Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Prin. Accounting Officer"}}],"security":"Common Stock","published_at":"2026-08-17T22:19:56.000Z","date":"2026-08-13","kind":"sale","planned":false,"acquired":false,"shares":3,"price":31.13,"value":93.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."}],"balance_after":48961,"source":{"system":"sec-edgar","filing":"0002138368-26-000007","document":"form4-08172026_100852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000213836826000007/form4-08172026_100852.xml","form_type":"4"}},{"id":685120,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22764,"kind":"person","name":"Meluzio Michael Vincent","position":1,"cik":"0002138368","reported_name":"Meluzio Michael Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Prin. Accounting Officer"}}],"security":"Common Stock","published_at":"2026-08-17T22:19:56.000Z","date":"2026-08-13","kind":"sale","planned":false,"acquired":false,"shares":4106,"price":30.35,"value":124617.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $29.99 to $30.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades."}],"balance_after":48964,"source":{"system":"sec-edgar","filing":"0002138368-26-000007","document":"form4-08172026_100852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000213836826000007/form4-08172026_100852.xml","form_type":"4"}},{"id":685119,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22764,"kind":"person","name":"Meluzio Michael Vincent","position":1,"cik":"0002138368","reported_name":"Meluzio Michael Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Prin. Accounting Officer"}}],"security":"Common Stock","published_at":"2026-08-17T22:19:56.000Z","date":"2026-08-13","kind":"sale","planned":false,"acquired":false,"shares":1519,"price":29.37,"value":44613.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $28.97 to $29.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades."}],"balance_after":53070,"source":{"system":"sec-edgar","filing":"0002138368-26-000007","document":"form4-08172026_100852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000213836826000007/form4-08172026_100852.xml","form_type":"4"}},{"id":685118,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22764,"kind":"person","name":"Meluzio Michael Vincent","position":1,"cik":"0002138368","reported_name":"Meluzio Michael Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Prin. Accounting Officer"}}],"security":"Common Stock","published_at":"2026-08-17T22:19:56.000Z","date":"2026-08-13","kind":"exercise","planned":false,"acquired":true,"shares":13647,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":54589,"source":{"system":"sec-edgar","filing":"0002138368-26-000007","document":"form4-08172026_100852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000213836826000007/form4-08172026_100852.xml","form_type":"4"}},{"id":686475,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:46:04.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":false,"shares":109179,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The performance stock units (\"PSU\") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 12, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The performance stock units (\"PSU\") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 12, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The performance stock units (\"PSU\") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 12, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days."}],"balance_after":218358,"derivative":{"underlying":"Common Stock","underlying_shares":109179},"source":{"system":"sec-edgar","filing":"0001725092-26-000013","document":"form4-08152026_120800.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000013/form4-08152026_120800.xml","form_type":"4"}},{"id":686474,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:46:04.000Z","date":"2026-08-13","kind":"sale","planned":false,"acquired":false,"shares":10460,"price":29.48,"value":308360.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $28.90 to $29.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades."}],"balance_after":705995,"source":{"system":"sec-edgar","filing":"0001725092-26-000013","document":"form4-08152026_120800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000013/form4-08152026_120800.xml","form_type":"4"}},{"id":686473,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:46:04.000Z","date":"2026-08-13","kind":"sale","planned":false,"acquired":false,"shares":2375,"price":28.11,"value":66761.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $27.78 to $28.505, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades."}],"balance_after":716455,"source":{"system":"sec-edgar","filing":"0001725092-26-000013","document":"form4-08152026_120800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000013/form4-08152026_120800.xml","form_type":"4"}},{"id":686472,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:46:04.000Z","date":"2026-08-13","kind":"sale","planned":false,"acquired":false,"shares":5423,"price":27.19,"value":147451.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $26.70 to $27.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades."}],"balance_after":718830,"source":{"system":"sec-edgar","filing":"0001725092-26-000013","document":"form4-08152026_120800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000013/form4-08152026_120800.xml","form_type":"4"}},{"id":686471,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:46:04.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":5775,"price":27.75,"value":160256.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $27.50 to $28.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades."}],"balance_after":724253,"source":{"system":"sec-edgar","filing":"0001725092-26-000013","document":"form4-08152026_120800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000013/form4-08152026_120800.xml","form_type":"4"}},{"id":686470,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:46:04.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":34225,"price":26.99,"value":923732.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $26.50 to $27.495, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades."}],"balance_after":730028,"source":{"system":"sec-edgar","filing":"0001725092-26-000013","document":"form4-08152026_120800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000013/form4-08152026_120800.xml","form_type":"4"}},{"id":686469,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:46:04.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":true,"shares":109179,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":764253,"source":{"system":"sec-edgar","filing":"0001725092-26-000013","document":"form4-08152026_120800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000013/form4-08152026_120800.xml","form_type":"4"}},{"id":698714,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":27147,"kind":"person","name":"Ahlers James M","position":1,"cik":"0001320383","reported_name":"Ahlers James M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:19:19.000Z","date":"2026-07-30","kind":"grant","planned":false,"acquired":true,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option becomes exercisable in equal quarterly installments over four years from July 30, 2026, subject to the reporting person's continued service with the issuer through each vest date."}],"balance_after":51000,"derivative":{"exercise_price":30.4,"expiration_date":"2036-07-30","underlying":"Common Stock","underlying_shares":51000},"source":{"system":"sec-edgar","filing":"0001320383-26-000006","document":"form4-08032026_080815.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1320383/000132038326000006/form4-08032026_080815.xml","form_type":"4"}},{"id":698713,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":27147,"kind":"person","name":"Ahlers James M","position":1,"cik":"0001320383","reported_name":"Ahlers James M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-03T20:19:19.000Z","date":"2026-07-30","kind":"grant","planned":false,"acquired":true,"shares":25500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"). The shares subject to the RSU vest in equal quarterly installments over four years from July 30, 2026, subject to the reporting person's continued service with the issuer through each vest date."}],"balance_after":25500,"source":{"system":"sec-edgar","filing":"0001320383-26-000006","document":"form4-08032026_080815.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1320383/000132038326000006/form4-08032026_080815.xml","form_type":"4"}},{"id":700495,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock Warrants (Right to Buy)","published_at":"2026-07-30T20:35:56.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":45453,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amendment is filed solely to correct the transaction code reported in Column 4 of Table II. The transactions reported herein were approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended, prior to the issuance of the applicable securities. All other information in the original filing remains unchanged."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On April 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023."}],"balance_after":45453,"derivative":{"exercise_price":11,"exercise_date":"2026-06-01","expiration_date":"2031-05-04","underlying":"Common Stock","underlying_shares":45453},"source":{"system":"sec-edgar","filing":"0001725092-26-000009","document":"form4a-07302026_080752.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000009/form4a-07302026_080752.xml","form_type":"4/A","original_submission_date":"2026-06-01"}},{"id":700494,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2026-07-30T20:35:56.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":90906,"price":11,"value":999966.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amendment is filed solely to correct the transaction code reported in Column 4 of Table II. The transactions reported herein were approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended, prior to the issuance of the applicable securities. All other information in the original filing remains unchanged."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On April 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The securities do not have an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023."}],"balance_after":90906,"derivative":{"exercise_price":0.001,"exercise_date":"2026-06-01","underlying":"Common Stock","underlying_shares":90906},"source":{"system":"sec-edgar","filing":"0001725092-26-000009","document":"form4a-07302026_080752.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000009/form4a-07302026_080752.xml","form_type":"4/A","original_submission_date":"2026-06-01"}},{"id":709174,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":30359,"kind":"person","name":"Borie Dominique Christian","position":1,"cik":"0002008790","reported_name":"Borie Dominique Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Medical Officer","other_text":"Head of Research & Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-15T22:59:46.000Z","date":"2026-07-13","kind":"grant","planned":false,"acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option becomes exercisable in equal quarterly installments over four years from July 13, 2026, subject to the reporting person's continued service with the issuer through each vest date."}],"balance_after":63000,"derivative":{"exercise_price":30.92,"expiration_date":"2036-07-13","underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0002008790-26-000006","document":"form4-07152026_100742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2008790/000200879026000006/form4-07152026_100742.xml","form_type":"4"}},{"id":709173,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":30359,"kind":"person","name":"Borie Dominique Christian","position":1,"cik":"0002008790","reported_name":"Borie Dominique Christian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Medical Officer","other_text":"Head of Research & Development"}}],"security":"Common Stock","published_at":"2026-07-15T22:59:46.000Z","date":"2026-07-13","kind":"grant","planned":false,"acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"). The shares subject to the RSU vest in equal quarterly installments over four years from July 13, 2026, subject to the reporting person's continued service with the issuer through each vest date."}],"balance_after":31500,"source":{"system":"sec-edgar","filing":"0002008790-26-000006","document":"form4-07152026_100742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008790/000200879026000006/form4-07152026_100742.xml","form_type":"4"}},{"id":711019,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":18637,"kind":"person","name":"Garzone Pamela","position":1,"cik":"0001974756","reported_name":"Garzone Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-10T23:37:59.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":21800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date."}],"balance_after":21800,"source":{"system":"sec-edgar","filing":"0001974756-26-000004","document":"form4-07102026_110755.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000197475626000004/form4-07102026_110755.xml","form_type":"4"}},{"id":711020,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":30934,"kind":"person","name":"Camardo Daniel A.","position":1,"cik":"0001820365","reported_name":"Camardo Daniel A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-10T23:37:10.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":21800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\").  One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date."}],"balance_after":21800,"source":{"system":"sec-edgar","filing":"0001820365-26-000009","document":"form4-07102026_110706.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000182036526000009/form4-07102026_110706.xml","form_type":"4"}},{"id":711018,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":30933,"kind":"person","name":"Meehan Viola Mong","position":1,"cik":"0002137444","reported_name":"Meehan Viola Mong","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-10T23:35:05.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":21800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date."}],"balance_after":21800,"source":{"system":"sec-edgar","filing":"0002137444-26-000007","document":"form4-07102026_110702.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000213744426000007/form4-07102026_110702.xml","form_type":"4"}},{"id":711017,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22764,"kind":"person","name":"Meluzio Michael Vincent","position":1,"cik":"0002138368","reported_name":"Meluzio Michael Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Prin. Accounting Officer"}}],"security":"Common Stock","published_at":"2026-07-10T23:34:24.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":40942,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents the grant of performance stock units (\"PSUs\"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents the grant of performance stock units (\"PSUs\"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents the grant of performance stock units (\"PSUs\"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration."}],"balance_after":40942,"derivative":{"underlying":"Common Stock","underlying_shares":40942},"source":{"system":"sec-edgar","filing":"0002138368-26-000005","document":"form4-07102026_110720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000213836826000005/form4-07102026_110720.xml","form_type":"4"}},{"id":711016,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22764,"kind":"person","name":"Meluzio Michael Vincent","position":1,"cik":"0002138368","reported_name":"Meluzio Michael Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Prin. Accounting Officer"}}],"security":"Common Stock","published_at":"2026-07-10T23:34:24.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":40942,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents that grant of restricted stock units (\"RSUs\").  The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date."}],"balance_after":40942,"source":{"system":"sec-edgar","filing":"0002138368-26-000005","document":"form4-07102026_110720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000213836826000005/form4-07102026_110720.xml","form_type":"4"}},{"id":711050,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22786,"kind":"person","name":"Ray Sumita","position":1,"cik":"0001579629","reported_name":"Ray Sumita","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Legal Compliance Officer","other_text":"Corporate Secretary"}}],"security":"Common Stock","published_at":"2026-07-10T23:33:18.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":54589,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents the grant of performance stock units (\"PSUs\"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents the grant of performance stock units (\"PSUs\"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents the grant of performance stock units (\"PSUs\"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration."}],"balance_after":54589,"derivative":{"underlying":"Common Stock","underlying_shares":54589},"source":{"system":"sec-edgar","filing":"0001579629-26-000004","document":"form4-07102026_110713.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579629/000157962926000004/form4-07102026_110713.xml","form_type":"4"}},{"id":711049,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":22786,"kind":"person","name":"Ray Sumita","position":1,"cik":"0001579629","reported_name":"Ray Sumita","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Legal Compliance Officer","other_text":"Corporate Secretary"}}],"security":"Common Stock","published_at":"2026-07-10T23:33:18.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":54589,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents that grant of restricted stock units (\"RSUs\").  The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date."}],"balance_after":109178,"source":{"system":"sec-edgar","filing":"0001579629-26-000004","document":"form4-07102026_110713.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579629/000157962926000004/form4-07102026_110713.xml","form_type":"4"}},{"id":711015,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-10T23:32:15.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":327537,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents the grant of performance stock units (\"PSUs\"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents the grant of performance stock units (\"PSUs\"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents the grant of performance stock units (\"PSUs\"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration."}],"balance_after":327537,"derivative":{"underlying":"Common Stock","underlying_shares":327537},"source":{"system":"sec-edgar","filing":"0001725092-26-000006","document":"form4-07102026_110711.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000006/form4-07102026_110711.xml","form_type":"4"}},{"id":711014,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-10T23:32:15.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":327537,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents that grant of restricted stock units (\"RSUs\").  The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date."}],"balance_after":655074,"source":{"system":"sec-edgar","filing":"0001725092-26-000006","document":"form4-07102026_110711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000006/form4-07102026_110711.xml","form_type":"4"}},{"id":711346,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":18808,"kind":"person","name":"Sarraf Pasha","position":1,"cik":"0002059447","reported_name":"Sarraf Pasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-10T19:36:10.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":21800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings held after the transaction reflects a 1-for-30 reverse split of the issuer's stock effected on April 22, 2026."}],"balance_after":32595,"source":{"system":"sec-edgar","filing":"0002059447-26-000004","document":"form4-07102026_110706.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2059447/000205944726000004/form4-07102026_110706.xml","form_type":"4"}},{"id":745766,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":30934,"kind":"person","name":"Camardo Daniel A.","position":1,"cik":"0001820365","reported_name":"Camardo Daniel A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T20:25:07.000Z","date":"2026-05-30","kind":"grant","planned":false,"acquired":true,"shares":1626,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments."}],"balance_after":1626,"derivative":{"exercise_price":21.9,"expiration_date":"2036-05-29","underlying":"Common Stock","underlying_shares":1626},"source":{"system":"sec-edgar","filing":"0001820365-26-000006","document":"form4-06082026_080603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000182036526000006/form4-06082026_080603.xml","form_type":"4"}},{"id":750814,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock Warrants (Right to Buy)","published_at":"2026-06-03T21:30:17.000Z","date":"2026-06-01","kind":"purchase","planned":false,"acquired":true,"shares":45453,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023."}],"balance_after":45453,"derivative":{"exercise_price":11,"exercise_date":"2026-06-01","expiration_date":"2031-05-04","underlying":"Common Stock","underlying_shares":45453},"source":{"system":"sec-edgar","filing":"0001725092-26-000004","document":"form4-06032026_090611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000004/form4-06032026_090611.xml","form_type":"4"}},{"id":750813,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2026-06-03T21:30:17.000Z","date":"2026-06-01","kind":"purchase","planned":false,"acquired":true,"shares":90906,"price":11,"value":999966.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The securities do not have an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023."}],"balance_after":90906,"derivative":{"exercise_price":0.001,"exercise_date":"2026-06-01","underlying":"Common Stock","underlying_shares":90906},"source":{"system":"sec-edgar","filing":"0001725092-26-000004","document":"form4-06032026_090611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000004/form4-06032026_090611.xml","form_type":"4"}},{"id":754029,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":30933,"kind":"person","name":"Meehan Viola Mong","position":1,"cik":"0002137444","reported_name":"Meehan Viola Mong","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T00:42:01.000Z","date":"2026-05-30","kind":"grant","planned":false,"acquired":true,"shares":1626,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments."}],"balance_after":1626,"derivative":{"exercise_price":21.9,"expiration_date":"2036-05-29","underlying":"Common Stock","underlying_shares":1626},"source":{"system":"sec-edgar","filing":"0002137444-26-000005","document":"form4-06032026_120657.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000213744426000005/form4-06032026_120657.xml","form_type":"4"}},{"id":788223,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-07T20:00:05.000Z","date":"2026-05-03","kind":"grant","planned":false,"acquired":true,"shares":655074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in 48 equal monthly installments beginning on April 30, 2026."}],"balance_after":655074,"derivative":{"exercise_price":30.42,"expiration_date":"2036-05-02","underlying":"Common Stock","underlying_shares":655074},"source":{"system":"sec-edgar","filing":"0001193125-26-211806","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526211806/ownership.xml","form_type":"4"}},{"id":788222,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-05-07T20:00:05.000Z","date":"2026-05-03","kind":"grant","planned":false,"acquired":true,"shares":327537,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":327537,"source":{"system":"sec-edgar","filing":"0001193125-26-211806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526211806/ownership.xml","form_type":"4"}},{"id":810450,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-10T20:00:06.000Z","date":"2026-04-09","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":0.29,"expiration_date":"2036-04-08","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001193125-26-151202","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000119312526151202/ownership.xml","form_type":"4"}},{"id":810622,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52936,"kind":"person","name":"Warren Lucinda","position":1,"cik":"0002035620","reported_name":"Warren Lucinda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-10T20:00:05.000Z","date":"2026-04-09","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter."}],"balance_after":250000,"derivative":{"exercise_price":0.29,"expiration_date":"2036-04-08","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001193125-26-151201","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2035620/000119312526151201/ownership.xml","form_type":"4"}},{"id":810626,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":42484,"kind":"person","name":"Baker Daniel G.","position":1,"cik":"0002046802","reported_name":"Baker Daniel G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF DEVELOPMENT OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-10T20:00:03.000Z","date":"2026-04-09","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter."}],"balance_after":100000,"derivative":{"exercise_price":0.29,"expiration_date":"2036-04-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-26-151200","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2046802/000119312526151200/ownership.xml","form_type":"4"}},{"id":946129,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":35630,"kind":"person","name":"Broadfoot Jill Marie","position":1,"cik":"0001305178","reported_name":"Broadfoot Jill Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:00:09.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option becomes fully exercisable on the first anniversary of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":0.34,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0001193125-26-004358","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1305178/000119312526004358/ownership.xml","form_type":"4"}},{"id":945650,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":18637,"kind":"person","name":"Garzone Pamela","position":1,"cik":"0001974756","reported_name":"Garzone Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:00:07.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option becomes fully exercisable on the first anniversary of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":0.34,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0001193125-26-004356","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526004356/ownership.xml","form_type":"4"}},{"id":945649,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":63030,"kind":"person","name":"Morich Frank","position":1,"cik":"0001748615","reported_name":"Morich Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:00:06.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option becomes fully exercisable on the first anniversary of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":0.34,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0001193125-26-004357","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526004357/ownership.xml","form_type":"4"}},{"id":945648,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69934,"kind":"person","name":"Verheyen Patrick","position":1,"cik":"0001972605","reported_name":"Verheyen Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:00:04.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option becomes fully exercisable on the first anniversary of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":0.34,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0001193125-26-004355","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526004355/ownership.xml","form_type":"4"}},{"id":945913,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T16:00:11.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option becomes fully exercisable on the first anniversary of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":0.34,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0001193125-26-004359","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000119312526004359/ownership.xml","form_type":"4"}},{"id":947424,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":18808,"kind":"person","name":"Sarraf Pasha","position":1,"cik":"0002059447","reported_name":"Sarraf Pasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T16:00:03.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option becomes fully exercisable on the first anniversary of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":0.34,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0001193125-26-004354","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2059447/000119312526004354/ownership.xml","form_type":"4"}},{"id":955423,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":18808,"kind":"person","name":"Sarraf Pasha","position":1,"cik":"0002059447","reported_name":"Sarraf Pasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-02T16:00:03.000Z","date":"2025-12-30","kind":"purchase","planned":false,"acquired":true,"shares":77417,"price":0.3016,"value":23348.9672,"ownership":{"direct":true},"balance_after":323857,"source":{"system":"sec-edgar","filing":"0001193125-26-000900","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2059447/000119312526000900/ownership.xml","form_type":"4"}},{"id":955422,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":18808,"kind":"person","name":"Sarraf Pasha","position":1,"cik":"0002059447","reported_name":"Sarraf Pasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-02T16:00:03.000Z","date":"2025-12-30","kind":"purchase","planned":false,"acquired":true,"shares":78116,"price":0.3114,"value":24325.3224,"ownership":{"direct":true},"balance_after":246440,"source":{"system":"sec-edgar","filing":"0001193125-26-000900","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2059447/000119312526000900/ownership.xml","form_type":"4"}},{"id":955421,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":18808,"kind":"person","name":"Sarraf Pasha","position":1,"cik":"0002059447","reported_name":"Sarraf Pasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-02T16:00:03.000Z","date":"2025-12-30","kind":"purchase","planned":false,"acquired":true,"shares":86947,"price":0.3174,"value":27596.9778,"ownership":{"direct":true},"balance_after":168324,"source":{"system":"sec-edgar","filing":"0001193125-26-000900","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2059447/000119312526000900/ownership.xml","form_type":"4"}},{"id":955420,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":18808,"kind":"person","name":"Sarraf Pasha","position":1,"cik":"0002059447","reported_name":"Sarraf Pasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-02T16:00:03.000Z","date":"2025-12-30","kind":"purchase","planned":false,"acquired":true,"shares":77148,"price":0.3003,"value":23167.5444,"ownership":{"direct":true},"balance_after":81377,"source":{"system":"sec-edgar","filing":"0001193125-26-000900","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2059447/000119312526000900/ownership.xml","form_type":"4"}},{"id":955419,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":18808,"kind":"person","name":"Sarraf Pasha","position":1,"cik":"0002059447","reported_name":"Sarraf Pasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-02T16:00:03.000Z","date":"2025-12-30","kind":"purchase","planned":false,"acquired":true,"shares":4229,"price":0.3094,"value":1308.4526,"ownership":{"direct":true},"balance_after":4229,"source":{"system":"sec-edgar","filing":"0001193125-26-000900","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2059447/000119312526000900/ownership.xml","form_type":"4"}},{"id":979099,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T23:54:26.000Z","date":"2025-12-03","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 24, 2024 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria for these shares was deemed satisfied or waived on December 3, 2025 and these shares underlying the option vested."}],"balance_after":70000,"derivative":{"exercise_price":0.7,"expiration_date":"2024-07-23","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001193125-25-310067","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000119312525310067/ownership.xml","form_type":"4"}},{"id":979098,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T23:54:26.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 24, 2024 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria for these shares was deemed satisfied or waived on September 26, 2025 and these shares underlying the option vested."}],"balance_after":30000,"derivative":{"exercise_price":0.7,"expiration_date":"2034-07-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-25-310067","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000119312525310067/ownership.xml","form_type":"4"}},{"id":988938,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52936,"kind":"person","name":"Warren Lucinda","position":1,"cik":"0002035620","reported_name":"Warren Lucinda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:00:05.000Z","date":"2025-09-29","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes fully exercisable on the first anniversary of the grant date."}],"balance_after":125000,"derivative":{"exercise_price":0.72,"expiration_date":"2035-09-28","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001193125-25-296986","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2035620/000119312525296986/ownership.xml","form_type":"4"}},{"id":988968,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":42484,"kind":"person","name":"Baker Daniel G.","position":1,"cik":"0002046802","reported_name":"Baker Daniel G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF DEVELOPMENT OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:00:04.000Z","date":"2025-09-29","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes fully exercisable on the first anniversary of the grant date."}],"balance_after":50000,"derivative":{"exercise_price":0.72,"expiration_date":"2035-09-28","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-25-296985","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2046802/000119312525296985/ownership.xml","form_type":"4"}},{"id":1026482,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":74623,"kind":"person","name":"Azam Usman","position":1,"cik":"0002089768","reported_name":"Azam Usman","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-10-03T00:13:23.000Z","date":"2025-09-29","kind":"grant","planned":false,"acquired":true,"shares":1875000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in 48 monthly installments beginning on September 29, 2026."}],"balance_after":1875000,"derivative":{"exercise_price":0.72,"expiration_date":"2035-09-28","underlying":"Common Stock","underlying_shares":1875000},"source":{"system":"sec-edgar","filing":"0001193125-25-228920","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312525228920/ownership.xml","form_type":"4"}},{"id":1119431,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":35630,"kind":"person","name":"Broadfoot Jill Marie","position":1,"cik":"0001305178","reported_name":"Broadfoot Jill Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T20:00:05.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":48800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 4, 2025. The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments."}],"balance_after":48800,"derivative":{"exercise_price":0.62,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":48800},"source":{"system":"sec-edgar","filing":"0000950170-25-083026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1305178/000095017025083026/ownership.xml","form_type":"4"}},{"id":1191926,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81565,"kind":"person","name":"Millar Kerri-Ann","position":1,"cik":"0001739126","reported_name":"Millar Kerri-Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-25T20:00:10.000Z","date":"2025-03-21","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025."}],"balance_after":200000,"derivative":{"exercise_price":0.99,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000950170-25-044348","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017025044348/ownership.xml","form_type":"4"}},{"id":1192473,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":42484,"kind":"person","name":"Baker Daniel G.","position":1,"cik":"0002046802","reported_name":"Baker Daniel G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF DEVELOPMENT OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-25T20:00:07.000Z","date":"2025-03-21","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025."}],"balance_after":100000,"derivative":{"exercise_price":0.99,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-044346","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2046802/000095017025044346/ownership.xml","form_type":"4"}},{"id":1192270,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-25T20:00:06.000Z","date":"2025-03-21","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025."}],"balance_after":200000,"derivative":{"exercise_price":0.99,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000950170-25-044345","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000095017025044345/ownership.xml","form_type":"4"}},{"id":1192453,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52936,"kind":"person","name":"Warren Lucinda","position":1,"cik":"0002035620","reported_name":"Warren Lucinda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-25T20:00:05.000Z","date":"2025-03-21","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025."}],"balance_after":250000,"derivative":{"exercise_price":0.99,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000950170-25-044344","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2035620/000095017025044344/ownership.xml","form_type":"4"}},{"id":1191925,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81564,"kind":"person","name":"Levisetti Matteo","position":1,"cik":"0001962444","reported_name":"Levisetti Matteo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-25T20:00:03.000Z","date":"2025-03-21","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025."}],"balance_after":250000,"derivative":{"exercise_price":0.99,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000950170-25-044343","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017025044343/ownership.xml","form_type":"4"}},{"id":1192090,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-25T16:00:09.000Z","date":"2025-03-21","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025."}],"balance_after":450000,"derivative":{"exercise_price":0.99,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000950170-25-044347","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000095017025044347/ownership.xml","form_type":"4"}},{"id":1210262,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":18808,"kind":"person","name":"Sarraf Pasha","position":1,"cik":"0002059447","reported_name":"Sarraf Pasha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-12T16:00:05.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":48800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 10, 2025. The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly\ninstallments."}],"balance_after":48800,"derivative":{"exercise_price":1.03,"expiration_date":"2035-03-09","underlying":"Common Stock","underlying_shares":48800},"source":{"system":"sec-edgar","filing":"0000950170-25-037889","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2059447/000095017025037889/ownership.xml","form_type":"4"}},{"id":1313346,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69934,"kind":"person","name":"Verheyen Patrick","position":1,"cik":"0001972605","reported_name":"Verheyen Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-03T21:00:19.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":1.09,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0000950170-25-001103","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017025001103/ownership.xml","form_type":"4"}},{"id":1313345,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":18637,"kind":"person","name":"Garzone Pamela","position":1,"cik":"0001974756","reported_name":"Garzone Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-03T21:00:17.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":1.09,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0000950170-25-001101","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017025001101/ownership.xml","form_type":"4"}},{"id":1313344,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":63030,"kind":"person","name":"Morich Frank","position":1,"cik":"0001748615","reported_name":"Morich Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-03T21:00:15.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":1.09,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0000950170-25-001107","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017025001107/ownership.xml","form_type":"4"}},{"id":1315854,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-03T21:00:12.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":1.09,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0000950170-25-001106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000095017025001106/ownership.xml","form_type":"4"}},{"id":1313927,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-03T16:00:10.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":1.09,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0000950170-25-001105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000095017025001105/ownership.xml","form_type":"4"}},{"id":1326413,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-12-18T16:00:04.000Z","date":"2024-12-16","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":1.03,"value":30900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.97 to $1.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range provided."}],"balance_after":164578,"source":{"system":"sec-edgar","filing":"0000950170-24-137860","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000095017024137860/ownership.xml","form_type":"4"}},{"id":1348529,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":42484,"kind":"person","name":"Baker Daniel G.","position":1,"cik":"0002046802","reported_name":"Baker Daniel G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF DEVELOPMENT OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-29T21:00:05.000Z","date":"2024-11-25","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an inducement stock option granted on November 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option will become exercisable over two years in equal, semi-annual installments beginning on May 25, 2025."}],"balance_after":200000,"derivative":{"exercise_price":1.06,"expiration_date":"2034-11-24","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000950170-24-131890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2046802/000095017024131890/ownership.xml","form_type":"4"}},{"id":1414251,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52936,"kind":"person","name":"Warren Lucinda","position":1,"cik":"0002035620","reported_name":"Warren Lucinda","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF BUSINESS OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-05T20:00:02.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in four equal semi-annual installments beginning on March 3, 2025."}],"balance_after":350000,"derivative":{"exercise_price":0.66,"expiration_date":"2034-09-02","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0000950170-24-103955","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2035620/000095017024103955/ownership.xml","form_type":"4"}},{"id":1486110,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81564,"kind":"person","name":"Levisetti Matteo","position":1,"cik":"0001962444","reported_name":"Levisetti Matteo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T20:00:11.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on December 5, 2024."}],"balance_after":125000,"derivative":{"exercise_price":1.65,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000950170-24-070565","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024070565/ownership.xml","form_type":"4"}},{"id":1486109,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":90136,"kind":"person","name":"Suri Anish","position":1,"cik":"0001739130","reported_name":"Suri Anish","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CSO"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T20:00:10.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on December 5, 2024."}],"balance_after":150000,"derivative":{"exercise_price":1.65,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000950170-24-070564","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024070564/ownership.xml","form_type":"4"}},{"id":1486865,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T20:00:07.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on December 5, 2024."}],"balance_after":60000,"derivative":{"exercise_price":1.65,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-070562","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000095017024070562/ownership.xml","form_type":"4"}},{"id":1486108,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81565,"kind":"person","name":"Millar Kerri-Ann","position":1,"cik":"0001739126","reported_name":"Millar Kerri-Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T20:00:02.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on December 5, 2024."}],"balance_after":60000,"derivative":{"exercise_price":1.65,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-070559","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024070559/ownership.xml","form_type":"4"}},{"id":1486160,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":90138,"kind":"person","name":"Fox Michael J","position":1,"cik":"0001589232","reported_name":"Fox Michael J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T16:00:08.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":48800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 5, 2024. The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments"}],"balance_after":48800,"derivative":{"exercise_price":1.65,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":48800},"source":{"system":"sec-edgar","filing":"0000950170-24-070563","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1589232/000095017024070563/ownership.xml","form_type":"4"}},{"id":1586867,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-08T21:00:15.000Z","date":"2024-03-06","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 6, 2024."}],"balance_after":175000,"derivative":{"exercise_price":1.94,"expiration_date":"2034-03-05","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-24-028613","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000095017024028613/ownership.xml","form_type":"4"}},{"id":1585940,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":90136,"kind":"person","name":"Suri Anish","position":1,"cik":"0001739130","reported_name":"Suri Anish","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CSO"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-08T21:00:14.000Z","date":"2024-03-06","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 6, 2024."}],"balance_after":300000,"derivative":{"exercise_price":1.94,"expiration_date":"2034-03-05","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000950170-24-028611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024028611/ownership.xml","form_type":"4"}},{"id":1585939,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81565,"kind":"person","name":"Millar Kerri-Ann","position":1,"cik":"0001739126","reported_name":"Millar Kerri-Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-08T21:00:12.000Z","date":"2024-03-06","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 6, 2024."}],"balance_after":250000,"derivative":{"exercise_price":1.94,"expiration_date":"2034-03-05","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000950170-24-028612","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024028612/ownership.xml","form_type":"4"}},{"id":1585938,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81564,"kind":"person","name":"Levisetti Matteo","position":1,"cik":"0001962444","reported_name":"Levisetti Matteo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-08T21:00:06.000Z","date":"2024-03-06","kind":"grant","planned":false,"acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 6, 2024."}],"balance_after":260000,"derivative":{"exercise_price":1.94,"expiration_date":"2034-03-05","underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0000950170-24-028608","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024028608/ownership.xml","form_type":"4"}},{"id":1586334,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-08T16:00:09.000Z","date":"2024-03-06","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 6, 2024."}],"balance_after":400000,"derivative":{"exercise_price":1.94,"expiration_date":"2034-03-05","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-24-028609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000095017024028609/ownership.xml","form_type":"4"}},{"id":1624560,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81564,"kind":"person","name":"Levisetti Matteo","position":1,"cik":"0001962444","reported_name":"Levisetti Matteo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-22T21:00:07.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 17, 2023 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria.  The performance-based vesting criteria was deemed satisfied or waived on February 20, 2024 and these shares underlying the option vested in full."}],"balance_after":25000,"derivative":{"exercise_price":3.36,"expiration_date":"2033-01-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-24-018724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024018724/ownership.xml","form_type":"4"}},{"id":1686912,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":18637,"kind":"person","name":"Garzone Pamela","position":1,"cik":"0001974756","reported_name":"Garzone Pamela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-04T21:02:45.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":2.78,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0000950170-24-001833","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024001833/ownership.xml","form_type":"4"}},{"id":1688605,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":31497,"kind":"person","name":"DRISCOLL FREDERICK W","position":1,"cik":"0001129890","reported_name":"DRISCOLL FREDERICK W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-04T21:02:02.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":2.78,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0000950170-24-001829","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129890/000095017024001829/ownership.xml","form_type":"4"}},{"id":1686911,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69934,"kind":"person","name":"Verheyen Patrick","position":1,"cik":"0001972605","reported_name":"Verheyen Patrick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-04T21:01:25.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":2.78,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0000950170-24-001828","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024001828/ownership.xml","form_type":"4"}},{"id":1686910,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":63030,"kind":"person","name":"Morich Frank","position":1,"cik":"0001748615","reported_name":"Morich Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-04T21:00:53.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":2.78,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0000950170-24-001827","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024001827/ownership.xml","form_type":"4"}},{"id":1687223,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":69958,"kind":"person","name":"Kiener Peter A","position":1,"cik":"0001328146","reported_name":"Kiener Peter A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-04T16:02:07.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":24400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date."}],"balance_after":24400,"derivative":{"exercise_price":2.78,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":24400},"source":{"system":"sec-edgar","filing":"0000950170-24-001830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328146/000095017024001830/ownership.xml","form_type":"4"}},{"id":1793861,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":90136,"kind":"person","name":"Suri Anish","position":1,"cik":"0001739130","reported_name":"Suri Anish","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CSO"}}],"security":"Common Stock","published_at":"2023-08-29T20:08:25.000Z","date":"2023-08-25","kind":"purchase","planned":false,"acquired":true,"shares":4000,"price":2.76,"value":11040.0,"ownership":{"direct":true},"balance_after":135638,"source":{"system":"sec-edgar","filing":"0001209191-23-047575","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000120919123047575/doc4.xml","form_type":"4"}},{"id":1805341,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81568,"kind":"person","name":"PASSERI DANIEL R","position":1,"cik":"0001190121","reported_name":"PASSERI DANIEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-08-16T16:07:47.000Z","date":"2023-08-14","kind":"purchase","planned":false,"acquired":true,"shares":3000,"price":2.86,"value":8580.0,"ownership":{"direct":true},"balance_after":134578,"source":{"system":"sec-edgar","filing":"0001209191-23-046000","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190121/000120919123046000/doc4.xml","form_type":"4"}},{"id":1823399,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81564,"kind":"person","name":"Levisetti Matteo","position":1,"cik":"0001962444","reported_name":"Levisetti Matteo","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-07-25T16:33:06.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in twenty four equal monthly installments beginning on August 21, 2023."}],"balance_after":82500,"derivative":{"exercise_price":4.2,"expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001209191-23-043278","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000120919123043278/doc4.xml","form_type":"4"}},{"id":1823397,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":81565,"kind":"person","name":"Millar Kerri-Ann","position":1,"cik":"0001739126","reported_name":"Millar Kerri-Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-07-25T16:31:14.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":113000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in twenty four equal monthly installments beginning on August 21, 2023."}],"balance_after":113000,"derivative":{"exercise_price":4.2,"expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":113000},"source":{"system":"sec-edgar","filing":"0001209191-23-043277","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000120919123043277/doc4.xml","form_type":"4"}}],"next_cursor":"2023-07-25T16:31:14.000000Z,1823397"}